ChIP-BIT2
ChIP-BIT2 identifies protein–DNA binding events from ChIP-seq data, emphasizing detection of weak binding sites at promoters and enhancers.
Key Features:
- Bayesian integration via mixture model: Employs a Bayesian integration approach using a mixture model to combine protein-specific and control ChIP-seq data.
- Weak binding detection: Differentiates weakly bound regions from amplified background DNA to improve detection of low-enrichment sites.
- Genomic localization: Predicts both strong and weak protein binding sites across genomic locations, including promoters and enhancers.
- Target gene prediction: Simultaneously predicts target genes associated with promoter-bound binding sites.
- Peak calling: Functions as a peak caller for ChIP-seq data to identify enriched regions.
- Validation: Validated using benchmark regions and large-scale ENCODE ChIP-seq datasets.
Scientific Applications:
- Detection of regulatory binding sites: Enables detection of weak protein–DNA interactions at promoters and enhancers that may regulate gene expression.
- Gene target assignment: Predicts promoter-bound target genes to link binding events to gene regulation.
- Regulatory network analysis: Extends the collection of known binding sites to support analysis of gene expression regulation and regulatory networks.
- Large-scale ChIP-seq analysis: Applicable to genome-wide ChIP-seq datasets such as ENCODE for comprehensive binding site discovery.
Methodology:
Uses Bayesian integration via a mixture model to combine protein-specific and control ChIP-seq data for distinguishing true binding signals from background.
Topics
Details
- Tool Type:
- command-line tool
- Operating Systems:
- Linux
- Programming Languages:
- C++
- Added:
- 6/14/2021
- Last Updated:
- 8/20/2021
Operations
Publications
Chen X, Shi X, Neuwald AF, Hilakivi-Clarke L, Clarke R, Xuan J. ChIP-BIT2: a software tool to detect weak binding events using a Bayesian integration approach. BMC Bioinformatics. 2021;22(1). doi:10.1186/s12859-021-04108-5. PMID:33858322. PMCID:PMC8051094.
PMID: 33858322
PMCID: PMC8051094
Funding: - National Cancer Institute: 149147, 149653, 164384
- National Institute of General Medical Sciences: 125878